Informace o publikaci

Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups

Autoři	PAJTLER Kristian W. WITT Henrik SILL Martin JONES David T. W. HOVESTADT Volker KRATOCHWIL Fabian WANI Khalida TATEVOSSIAN Ruth PUNCHIHEWA Chandanamali JOHANN Pascal REIMAND Jueri WARNATZ Hans-Joerg RYZHOVA Marina MACK Steve RAMASWAMY Vijay CAPPER David SCHWEIZER Leonille SIEBER Laura WITTMANN Andrea HUANG Zhiqin SLUIS Peter van VOLCKMANN Richard KOSTER Jan VERSTEEG Rogier FULTS Daniel TOLEDANO Helen AVIGAD Smadar HOFFMAN Lindsey M. DONSON Andrew M. FOREMAN Nicholas HEWER Ekkehard ZITTERBART Karel GILBERT Mark ARMSTRONG Terri S. GUPTA Nalin ALLEN Jeffrey C. KARAJANNIS Matthias A. ZAGZAG David HASSELBLATT Martin KULOZIK Andreas E. WITT Olaf COLLINS V. Peter HOFF Katja von RUTKOWSKI Stefan PIETSCH Torsten BADER Gary YASPO Marie-Laure DEIMLING Andreas von LICHTER Peter TAYLOR Michael D. GILBERTSON Richard ELLISON David W. ALDAPE Kenneth KORSHUNOV Andrey KOOL Marcel PFISTER Stefan M.
Rok publikování	2015
Druh	Článek v odborném periodiku
Časopis / Zdroj	Cancer Cell
Fakulta / Pracoviště MU	Lékařská fakulta
Citace
Doi	http://dx.doi.org/10.1016/j.ccell.2015.04.002
Obor	Onkologie a hematologie
Klíčová slova	POSTERIOR-FOSSA EPENDYMOMAS; PEDIATRIC INTRACRANIAL EPENDYMOMAS; CENTRAL-NERVOUS-SYSTEM; NF-KAPPA-B; CHILDHOOD EPENDYMOMAS; MUTATIONS; MEDULLOBLASTOMA; SUBGROUPS; GENE; GLIOBLASTOMA
Popis	Ependymal tumors across age groups are currently classified and graded solely by histopathology. It is, however, commonly accepted that this classification scheme has limited clinical utility based on its lack of reproducibility in predicting patients' outcome. We aimed at establishing a uniform molecular classification using DNA methylation profiling. Nine molecular subgroups were identified in a large cohort of 500 tumors, 3 in each anatomical compartment of the CNS, spine, posterior fossa, supratentorial. Two supratentorial subgroups are characterized by prototypic fusion genes involving RELA and YAP1, respectively. Regarding clinical associations, the molecular classification proposed herein outperforms the current histopathological classification and thus might serve as a basis for the next World Health Organization classification of CNS tumors.